Kintara Therapeutics, Inc. (NasdaqCM:KTRA) announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value. Kintara has engaged Ladenburg Thalmann & Co. Inc. to act as financial advisor for this process.

There can be no assurance that this exploration of strategic alternatives will result in the Company entering or completing any transaction. Kintara does not intend to make any further disclosures regarding the strategic review process unless and until a specific course of action is approved.